European journal of breast health最新文献

{"title":"Rosai-Dorfman Disease Presenting With FDG-Avid Breast Masses and Axillary Lymph Nodes on PET-CT in a Patient With Recent Diagnosis of Endometrial Carcinoma: A Diagnostic Dilemma.","authors":"Jennifer Kudja-Rennick, Pai Raghav, Cedric Pluguez-Turull, Katherine Drews-Elger, Cristina Hoyos","doi":"10.4274/ejbh.galenos.2024.2024-9-2","DOIUrl":"10.4274/ejbh.galenos.2024.2024-9-2","url":null,"abstract":"<p><p>Rosai-Dorfman disease (RDD) is a self-limited, idiopathic, non-neoplastic disorder characterized by the proliferation of phagocytic histiocytes, which can mimic malignant lymphoproliferative disease. Cases of RDD most commonly present as bilateral painless cervical lymphadenopathy, with lesser involvement of the axilla, inguinal, and mediastinal lymph nodes. We present the case of a 62-year-old woman with a history of endometrial serous carcinoma who underwent evaluation at a dedicated breast imaging department after positron emission tomography/computed tomography (PET/CT) revealed breast masses and axillary nodes with increased uptake of fluorodeoxyglucose (FDG). Upon clinical examination, she had bilateral palpable lumps in both breasts and axillae. Subsequent dedicated breast imaging with bilateral diagnostic mammography with tomosynthesis and bilateral complete breast ultrasound were suspicious for malignancy detecting bilateral breast masses and axillary lymphadenopathy corresponding to the FDG-avid findings on PET/CT. Ultrasound-guided core needle biopsies, however, revealed a diagnosis of RDD. This case highlights the unique characteristics of RDD with an atypical clinical presentation suspicious for breast cancer both clinically and radiologically.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"74-79"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and ¹⁸F-FDG PET/CT.","authors":"Reem Yusuf AlBuainain, Fatema Yusuf Bunajem, Hussain Adnan Abdulla","doi":"10.4274/ejbh.galenos.2024.2024-8-2","DOIUrl":"10.4274/ejbh.galenos.2024.2024-8-2","url":null,"abstract":"<p><strong>Objective: </strong>Neoadjuvant chemotherapy (NACT) has been the primary treatment method for patients with local advanced breast cancer. A pathological complete response (pCR) to therapy correlates with better overall disease prognosis. Magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) have been widely used to monitor the response to NACT in breast cancer. The aim of this study was to assess tumor response to NACT by MRI and PET/CT, to determine which imaging modality is more accurate in detecting tumor response post NACT in breast cancer.</p><p><strong>Materials and methods: </strong>A retrospective review of our database revealed 34 women with breast cancer that had MRI and PET/CT performed prior to and after NACT, followed by definitive surgery. For response assessment, we calculated the difference in maximum diameter of the tumor in MRI and difference in standard uptake values in PET/CT. The correspondence rate between the imaging modalities and pCR were calculated. For the prediction of pCR, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy where analyzed.</p><p><strong>Results: </strong>The assessment of tumor response to NACT showed 11 cases with pCR (32%), 15 pathological partial response (44%) and eight pathological no response (24%). The correspondence rate between MRI and pathological response was 50% (17/34), compared to 65% (22/34) for PET/CT. For prediction of pCR, MRI showed higher specificity compared to PET/CT (78.2% <i>vs.</i> 73.9%, <i>p</i> = 0.024), while the accuracy of PET/CT was significantly higher (79.4% <i>vs.</i> 70.5%, <i>p</i> = 0.004). PET/CT also had a higher NPV compared to MRI (94.4% <i>vs.</i> 78.2%, <i>p</i> = 0.002). There were no differences in terms of sensitivity and PPV between MRI and PET/CT.</p><p><strong>Conclusion: </strong>Compared to MRI, PET/CT was more likely to correlate with the pathological response after NACT. For the prediction of pCR, PET/CT proved to be a more accurate imaging modality to monitor response after NACT than MRI.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"46-51"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Level of Awareness, Screening Practices, and Self-Detection Among Breast Cancer Patients.","authors":"Ahmed Nawzad Hassan, Mustafa Saber Al-Attar","doi":"10.4274/ejbh.galenos.2024.2024-5-6","DOIUrl":"10.4274/ejbh.galenos.2024.2024-5-6","url":null,"abstract":"<p><strong>Objective: </strong>Having good knowledge and performing regular pre-tests under physician supervision play a crucial role in the early detection of breast cancer. The aim of this study was to investigate the level of awareness, frequency of performing routine screening, types of screening methods prior to detection, and who detected the case, among women diagnosed with breast cancer.</p><p><strong>Materials and methods: </strong>A cross-sectional study that used a designed questionnaire applied to investigate demographic data and four other aspects: level of awareness, screening practices, type of screening methods used, and who detected the case for the first time. Women who were diagnosed with breast cancer and registered at Nanakali Hospital were included.</p><p><strong>Results: </strong>A total of 150 women participated. Most of the participants (80%) had no previous knowledge regarding causes, signs and symptoms, or detection methods, while only 20% had little information. Among the participants, most (87.3%) did not undergo any pre-tests before the time of diagnosis, while only 12.7% did pre-test at least once. The screening methods used prior to the diagnosis were: breast self-exam (n=9); ultrasonography (n=8), and only two had mammography. Detecting the case for the first time, 68.7% of the cases were detected by chance or accidentally, and 31.3% were detected by physicians.</p><p><strong>Conclusion: </strong>The level of awareness and performance of routine screening differ greatly among different populations and countries. Women in Erbil, generally have a low level of awareness and insufficient knowledge regarding breast cancer; most women do not undertake any regular screening for early detection of this cancer compared to Western countries. Having previous knowledge and doing pre-tests regularly play a key role in the early detection of this cancer, which minimizes the consequences.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"52-56"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise.","authors":"Filiz Çelebi, Onur Tuncer, Müge Oral, Tomris Duymaz, Tolga Orhan, Gökhan Ertaş","doi":"10.4274/ejbh.galenos.2024.2024-9-7","DOIUrl":"10.4274/ejbh.galenos.2024.2024-9-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate integrating an artificial intelligence (AI) system into diagnostic breast ultrasound (US) for improved performance.</p><p><strong>Materials and methods: </strong>Seventy suspicious breast mass lesions (53 malignant and 17 benign) from seventy women who underwent diagnostic breast US complemented with shear wave elastography, US-guided core needle biopsy and verified histopathology were enrolled. Two radiologists, one with 15 years of experience and the other with one year of experience, evaluated the images for breast imaging-reporting and data system (BI-RADS) scoring. The less-experienced radiologist re-evaluated the images with the guidance of a commercial AI system and the maximum elasticity from shear wave elastography. The BI-RADS scorings were processed to determine diagnostic performance and malignancy detections.</p><p><strong>Results: </strong>The experienced reader demonstrated superior performance with an area under the curve (AUC) of 0.888 [95% confidence interval (CI): 0.793-0.983], indicating high diagnostic accuracy. In contrast, the Koios decision support (DS) system achieved an AUC of 0.693 (95% CI: 0.562-0.824). The less-experienced reader, guided by both Koios and elasticity, showed an AUC of 0.679 (95% CI: 0.534-0.823), while Koios alone resulted in an AUC of 0.655 (95% CI: 0.512-0.799). Without any guidance, the less-experienced reader exhibited the lowest performance, with an AUC of 0.512 (95% CI: 0.352-0.672). The experienced reader had a sensitivity of 98.1%, specificity of 58.8%, positive predictive value of 88.1%, negative predictive value of 90.9%, and overall accuracy of 88.6%. The Koios DS showed a sensitivity of 92.5%, specificity of 35.3%, and an accuracy of 78.6%. The less-experienced reader, when guided by both Koios and elasticity, achieved a sensitivity of 92.5%, specificity of 23.5%, and an accuracy of 75.7%. When guided by Koios alone, the less-experienced reader had a sensitivity of 90.6%, specificity of 17.6%, and an accuracy of 72.9%. Lastly, the less-experienced reader without any guidance showed a sensitivity of 84.9%, specificity of 17.6%, and an accuracy of 68.6%.</p><p><strong>Conclusion: </strong>Diagnostic evaluation of the suspicious masses on breast US images largely depends on experience, with experienced readers showing good performances. AI-based guidance can help improve lower performances, and using the elasticity metric may further improve the performances of less experienced readers. This type of guidance may reduce unnecessary biopsies by increasing the detection rate for malignant lesions and deliver significant benefits for routine clinical practice in underserved areas where experienced readers may not be available.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"33-39"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyoderma Gangrenosum: A Nightmare for Breast Surgery-Two Case Reports.","authors":"Gülşen Akoğlu, Murat Demiriz, Kerim Bora Yılmaz","doi":"10.4274/ejbh.galenos.2024.2024-7-5","DOIUrl":"10.4274/ejbh.galenos.2024.2024-7-5","url":null,"abstract":"<p><p>Pyoderma gangrenosum (PG) is a rare, chronic, neutrophilic dermatosis characterized by painful ulcers that are often misdiagnosed as wound infections. We report two cases of postsurgical PG following breast surgery: A 46-year-old woman with a non-healing ulcer after a breast biopsy and a 37-year-old woman with wound dehiscence after bilateral reduction mammoplasty. Both cases were initially managed with repeated debridements, antibiotics, and wound care without improvement. The diagnosis of PG was made based on the increase in wound size and irregularity. Treatment with oral doxycycline and topical tacrolimus led to favorable healing within four months. Breast surgical tehniques, which aim to achieve aesthetic results using intraglandular flaps, have become an important part of clinical practice in breast surgery. Early diagnosis and appropriate management are crucial in postsurgical PG to avoid misdiagnosis and ineffective treatments that cause patient disfigurement.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"80-84"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Effects of Intraparenchymal and Peritumoral Application of Isosulfan Blue Dye in Sentinel Lymph Node Mapping in Breast Cancer: A Systematic Review and Meta-Analysis.","authors":"Joshua Agilinko, Aditya Borakati, Andrel Yoong, Ponnuthurai Pratheepan, Suzette Samlalsingh","doi":"10.4274/ejbh.galenos.2024.2024-8-1","DOIUrl":"10.4274/ejbh.galenos.2024.2024-8-1","url":null,"abstract":"<p><p>We investigate the evidence for adverse effects of intraparenchymal and peritumoral application of isosulfan blue dye in sentinel lymph node (SLN) mapping in breast cancer patients. A meta-analysis on the adverse effects of intraparenchymal and peritumoral application of isosulfan application in SLN mapping was conducted using Medline and Embase databases up to 2023. Procedure-based adverse reactions were divided into three grades: Grade I (allergic skin reactions), Grade II (hypotension) and Grade III (requiring vasopressor support). Heterogeneity was expressed with I-squared and tau statistics. Subgroup analysis was conducted for administrative route. Univariable meta-regression was performed to assess dose-response effect on adverse reactions. Sensitivity analysis was conducted using fixed effect modelling. A total of 19,183 patients were identified from eight studies. The pooled total adverse event rate after isosulfan administration was 11.65 events per 1,000 patients [95% confidence interval (CI) 7.44-18.19]. The rate of Grade I reactions was 7.96 per 1,000 (95% CI 4.08-15.46); Grade II 0.08 per 1,000 (95% CI 0.00-1.31), Grade III 1.86 per 1,000 (95% CI 0.94-3.66), with no reported mortalities. Intraparenchymal administration was associated with 15.16 events per 1,000 (95% 8.64-26.45), versus 7.04 events per 1,000 (95% CI 5.24-9.45) in peritumoral administration (p=0.02). Univariable meta-regression did not show a significant association between volume of dye infused and total adverse events (-0.164 events per mL, 95% CI -0.864 to 0.534, p=0.645). Isosulfan has low adverse event rates regardless of injection technique or volume administered. Clinicians should have a high level of confidence in its use as an agent for SLN mapping, especially when administering it peritumorally.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conformable Ultrasound Breast Patch - The Future of Breast Cancer Screening?","authors":"Andreas Giannakou, Canan Dagdeviren, Tolga Ozmen","doi":"10.4274/ejbh.galenos.2024.2024-11-3","DOIUrl":"10.4274/ejbh.galenos.2024.2024-11-3","url":null,"abstract":"<p><p>Breast cancer is the most common cancer type among women worldwide with an average lifetime risk of 12.9%. Early detection and screening are the most important factors for improved prognosis and mammography remains the main screening tool for the average risk patients. Ultrasound (US) is used in women with elevated breast cancer risk, younger patients and patients with extremely dense breasts. Conventional US has certain limitations including operator dependence and reported low specificity. We designed a conformable US device (cUSBr-Patch) which offers large-area, deep tissue scanning and multi-angle, repeatable breast imaging. It is able to detect lesions as small as 1mm with excellent accuracy and reliability validated by <i>in vivo</i> comparison with conventional US. This is a user-friendly, innovating device designed to be used by patients with the potential to reshape our approach to breast cancer screening.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"90-92"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Review on Current Knowledge and Future Potential of Topical Therapies in Breast Cancer Treatment.","authors":"N Bharathi Sai Thilagam, V P Karthik, R Gnanasambandan, C Sowmya","doi":"10.4274/ejbh.galenos.2024.2024-9-9","DOIUrl":"10.4274/ejbh.galenos.2024.2024-9-9","url":null,"abstract":"<p><p>Breast cancer remains one of the most prevalent malignancies among women globally. Despite advances in therapeutic options, the prognosis often remains challenging. Breast cancer typically originates in the epithelial lining of glandular tissue ducts (85%) or lobules (15%). Initially confined to these areas (<i>in situ</i>), it generally remains asymptomatic and poses little risk of metastasis. The primary treatments for breast cancer include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Although these interventions have advanced significantly and have improved patient survival rates, they are connected with numerous im mediate and long-term side effects. Effective breast cancer treatment aims to maximize efficacy while minimizing adverse effects. Given that many breast cancers are specific to the breast, developing safe and targeted therapeutic strategies will be of benefit. This review examined the current literature on the effectiveness of topical therapies for breast cancer. Studies and clinical trials were evaluated that have investigated these treatments, focusing on their safety, ease of application, and patient acceptance. Recently, topical drug delivery is transforming breast cancer therapy, offering precision and reduced systemic toxicity. Emu oil-enhanced tamoxifen showed superior transdermal effectiveness, while raloxifene gel achieved 2.77 times greater bioavailability than oral forms. Tamoxifen nanoemulgels and microneedle arrays with resveratrol further enhanced localized delivery, These therapies have gained patient acceptance due to their non-invasive nature, lack of gastrointestinal side effects, ease of application, and favourable safety and therapeutic profiles and setting a new benchmark for innovative and patient-friendly treatments. This review summarizes the findings from various studies, highlighting the benefits and limitations of topical therapies. Topical therapies offer a promising noninvasive option for breast cancer treatment with fewer side effects. These treatments have shown favorable therapeutic and safety profiles, making them an attractive option for patients.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"21 1","pages":"9-15"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overexpression of <i>CDC25A, AURKB</i>, and <i>TOP2A</i> Genes Could Be an Important Clue for Luminal A Breast Cancer.","authors":"Murat Kaya, Asmaa Abuaisha, İlknur Süer, Melike Sultan Alptekin, Fahrünnisa Abanoz, Selman Emiroğlu, Şükrü Palanduz, Kıvanç Cefle, Şükrü Öztürk","doi":"10.4274/ejbh.galenos.2024.2024-4-3","DOIUrl":"10.4274/ejbh.galenos.2024.2024-4-3","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer (BC) is highly heterogeneous and one of the most common cancers. Luminal A (LUM A) is a subtype of BC with a better prognosis than other BC subtypes. The molecular mechanisms underlying the initiation and progression of the LUM A subtype are still unclear. Big data generated from microarray and sequencing systems can be re-analyzed, especially with the help of various <i>in silico</i> tools developed in recent years, and made applicable for <i>in vitro</i> and <i>in vivo</i> research. This work aimed to identify genes that may play a role in the progression of LUM A subtype of BC using both computational and laboratory-based methods.</p><p><strong>Materials and methods: </strong>Overlapping genes associated with BC were identified from the The Cancer Genome Atlas database, GSE233242, GSE100925 geodata sets, and the geneshot tool. The network functional analysis between overlapping genes was determined with STRING 12.0. Expression levels of overlapping genes in BC were investigated with the TNMplot (https://tnmplot.com/analysis/) <i>in silico</i> tool. The effect of overlapping genes on the overall survival of LUM A cancer patients was defined using the Kaplan-Meier plotter tool. Expressions of genes identified using bioinformatics data were investigated via quantitative real-time -polymerase chain reaction (qRT-PCR) in LUM A tumor and adjacent tissue samples. The data were evaluated using the t-test. Both the sensitivity and specificity of selected genes have been determined using the receiver operating characteristic curve.</p><p><strong>Results: </strong><i>In silico</i> investigation showed that eleven genes were possibly associated with BC. Among them <i>CDC25A, AURKB</i>, and <i>TOP2A</i> were considerably increased in LUM A samples according to qRT-PCR results. An overall survival analysis also showed that overexpression of these three genes could reduce the overall survival of LUM A patients.</p><p><strong>Conclusion: </strong>The genes <i>CDC25A, AURKB</i>, and <i>TOP2A</i> may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"284-291"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability of L-Dex Scores for Assessment of Unilateral Breast Cancer-Related Lymphedema.","authors":"Leigh C Ward, Katrina Gaitatzis, Belinda Thompson, Vincent Singh Paramanandam, Louise A Koelmeyer","doi":"10.4274/ejbh.galenos.2024.2024-5-7","DOIUrl":"10.4274/ejbh.galenos.2024.2024-5-7","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that may result in swelling of the affected arm due to compromised lymphatic function. Implementing a screening program and early intervention for BCRL are important for effective management. Bioimpedance spectroscopy (BIS) is a commonly used tool for assessing BCRL. This study aimed to compare different normative ranges for BIS L-Dex scores in the detection of BCRL.</p><p><strong>Materials and methods: </strong>Data from 158 women with clinically ascribed and indocyanine green confirmed BCRL were analysed. BIS measurements were obtained using an ImpediMed standing device, and L-Dex scores were calculated using published normative ranges for healthy individuals. Statistical analysis was performed to compare the concordance between different reference ranges in classifying individuals with lymphedema.</p><p><strong>Results: </strong>The study found that L-Dex scores calculated using different normative ranges were highly correlated and essentially interchangeable in detecting BCRL. Approximately 90% of participants exceeded the L-Dex threshold for lymphedema, with minimal discrepancies between reference ranges. False negative rates were observed in some participants, likely due to early-stage BCRL with minimal lymph accumulation.</p><p><strong>Conclusion: </strong>The findings suggest that BIS L-Dex scores are a valid indicator of BCRL, regardless of specific normative ranges used. Detection rates of clinically confirmed BCRL were consistent across different reference ranges, with minimal discrepancies. BIS remains a valuable tool for early detection and monitoring of BCRL. Future research should focus on longitudinal assessments and use of change in L-Dex scores for lymphedema monitoring and progression.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"251-257"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}